Cortistatin 14(mouse,rat) cas: 186901-48-4

CAS NO: 186901-48-4
Cortistatin 14(mouse,rat)
Chemical Name: CORTISTATIN-14
Molecular Formula: C81H114N20O18S2
Formula Weight: 1720.03
CAS No.: 186901-48-4
Description Review
Description

Cortistatin 14 is a peptide that has been identified in the brain and peripheral tissues of mice and rats. It belongs to a family of neuropeptides that are similar to somatostatin, which plays an important role in regulating the release of hormones such as growth hormone and insulin. Cortistatin 14 has been shown to have a wide range of potential health benefits, including anti-inflammatory, neuroprotective, and antitumor effects.

Chemical Name: L-Lysine, N^6-(1-iminoethyl)-5-oxo-, (L)-cyclo(L-histidyl-L-prolyl)- Molecular Formula: C28H42N8O5 Formula Weight: 602.70 g/mol CAS No: 186901-48-4

Top Ten Keywords from Google and Synonyms:

  1. neuropeptide
  2. somatostatin
  3. anti-inflammatory
  4. neuroprotective
  5. antitumor
  6. endocrine system
  7. immune system
  8. neurotransmitter
  9. hypothalamus
  10. pituitary gland

Synonyms:

  • Cortistatin-14
  • CST-14
  • Cyclo(L-His-L-Pro)

Health Benefits of this Product: Several studies suggest that cortistatin 14 has numerous health benefits. It has been shown to have potent anti-inflammatory effects, reducing inflammation in various organs and tissues, including the lungs, liver, kidneys, and brain. This anti-inflammatory effect may make it useful in treating inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and multiple sclerosis.

Cortistatin 14 also has neuroprotective effects, protecting neurons from damage caused by oxidative stress, inflammation, and other harmful processes. This may make it useful for treating and preventing neurodegenerative diseases such as Alzheimer's and Parkinson's.

Additionally, studies have shown that cortistatin 14 has antitumor effects, inhibiting the growth and proliferation of cancer cells in vitro and in vivo. This suggests that it may be useful in treating various types of cancer, although more research is needed to fully understand its potential in this regard.

Potential Effects: Cortistatin 14 acts on the endocrine system, immune system, and nervous system. It is involved in regulating the release of hormones such as growth hormone, insulin, and glucagon, and it modulates the activity of neurotransmitters such as dopamine, serotonin, and acetylcholine. Additionally, it has been shown to have direct effects on cells in various organs and tissues, including the lungs, liver, kidneys, and brain.

Product Mechanism: The exact mechanism of action of cortistatin 14 is not yet fully understood. However, it is believed to act on specific receptors in the brain and peripheral tissues, modulating the activity of various signaling pathways. It may also act indirectly through its effects on hormones and neurotransmitters.

Safety: Cortistatin 14 appears to be safe when used at appropriate doses. However, like all peptides, it may cause allergic reactions or other adverse effects in some people. Additionally, because it is a relatively new compound, there is limited information available about its long-term safety.

Side Effects: There are no known side effects of cortistatin 14 at this time. However, as with any new compound, it is important to monitor for potential side effects as more research on this product is conducted.

Dosing Information: The optimal dose of cortistatin 14 has not yet been established. However, studies in rodents have used doses ranging from 0.1 to 10 mg/kg, administered either intravenously or subcutaneously. More research is needed to determine the optimal dosing regimen for humans.

Conclusion: Cortistatin 14 is a promising peptide with a wide range of potential health benefits. Its anti-inflammatory, neuroprotective, and antitumor effects make it a potentially valuable therapeutic agent for a variety of conditions. However, further research is needed to fully understand its mechanisms of action, safety profile, and optimal dosing regimen.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code